Targeting MYC and BCL2 by a natural compound for “double-hit” lymphoma

Xiaqian Liu1,2 | Senlin Xu2 | Jiawei Zhang2 | Mingjie Fan2 | Jun Xie3 |
Bingfeng Zhang3 | Hongzi Li3 | Guohua Yu4 | Yinghui Liu1 |
Yuanfeng Zhang1 | Joo Song5 | David Horne3 | Wing C. Chan5 |
Xiaoxia Chu1 | Wendong Huang2

1Department of Hematology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China
2Molecular and Cellular Biology of Cancer Program & Department of Diabetes Complications and Metabolism, Beckman Research Institute, City of Hope, Duarte, California, USA
3Department of Molecular Medicine, City of Hope National Medical Center, Duarte, California, USA
4Department of Pathology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China
5Department of Pathology, City of Hope National Medical Center, Duarte, California, USA

Correspondence
Wing C. Chan, Department of Pathology, City of Hope National Medical Center, 1500 East Duarte Road, Duarte 91010, California, USA. Email: jochan@coh.org
Xiaoxia Chu, Department of Hematology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, 264000, China. Email: lucychu66@163.com
Wendong Huang, Molecular and Cellular Biology of Cancer Program & Department of Diabetes Complications and Metabolism, Beckman Research Institute, City of Hope, 1500 East Duarte Road, Duarte 91010, California, USA. Email: whuang@coh.org

Funding information
National Cancer Institute, Grant/Award Numbers: P30CA033572, R01CA139158; City of Hope, Grant/Award Numbers: IDDV program, TSLC pilot grant award

Abstract
Concurrent translocations of MYC and BCL2 lead to abnormal expression of both oncoproteins, which contribute to the aggressive clinical characteristics of double-hit lymphoma (DHL). An effective therapy for DHL remains an unmet clinical need. In this study, we showed that both Ca2+/calmodulin-dependent protein kinase II δ (CAMKIIδ) and γ (CAMKIIγ) were highly expressed in DHL. Both isoforms of CAMKII stabilize c-Myc protein by phosphorylating it at Ser62, increase BCL2 expression, and promote DHL tumor growth. Inhibition of CAMKIIδ and CAMKIIγ by either berbamine (BBM) or one of its derivatives (PA4) led to the downregulation of c-Myc and BCL2 proteins. BBM/PA4 also exhibited anti-tumor efficacy in DHL cell lines and NSG xenograft models. Altogether, CAMKIIδ and CAMKIIγ appear to be critical for DHL tumor development and are promising therapeutic targets for DHL.

KEYWORDS
Bcl2, berbamine, c-Myc, cancer treatment, double-hit lymphoma

Xiaohai Liu and Senlin Xu authors contribute equally.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.

Hematological Oncology. 2022;40:356-369. wileyonlinelibrary.com/journal/hon
1 | INTRODUCTION

In the most recent WHO classification of lymphoid tumors, a unique category was established for both “double-hit” lymphoma (DHL) and “triplet-hit” lymphoma (THL). These two B-cell lymphomas were separated from diffuse large B cell lymphoma (DLBCL) and designated in a new category called high-grade B-cell lymphoma (HGBL) with translocations of MYC, BCL2, and/or BCL6. DHL shows highly aggressive clinical features in advanced stages, rapid progression, and a propensity to involve the central nervous system. Patients with this subtype of lymphoma have poor outcomes when treated with the conventional immune-chemotherapy Rituximab with cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisolone (RCHOP). Therefore, to better understand the molecular pathogenesis of DHL and develop new therapeutic approaches are urgent.

Concurrent translocations of MYC and BCL2 lead to abnormal expression of both oncproteins. Effective strategies to treat DHL may involve targeting MYC and/or BCL2. Previously, we have been developing approaches to target MYC indirectly. In our studies, CAMKII stabilizes c-Myc by directly phosphorylating Serine 62 (S62). When CAMKIIy is inhibited with a natural compound called berbamine (BBM), this process can be suppressed, leading to c-Myc protein degradation. Accordingly, BBM suppressed the growth of T cell lymphoma both in vitro and in vivo. Based on the BBM chemical structure, we have developed several new derivatives. One derivative, termed PA4, inhibited both CAMKIIy and CAMKIIδ, and showed more potent activity than BBM in killing lymphoma cells.

ABT199 (Venetoclax) is a highly selective inhibitor of BCL2. It has been approval by the FDA for treating either chronic lymphocytic leukemia or small lymphocytic lymphoma. Moreover, several studies suggest that ABT199 is a promising drug for treating DHL. Low concentrations of ABT199 effectively induced cell apoptosis in “double-protein expression” lymphoma with MYC and BCL2 rearrangements.

Given this landscape, we hypothesize that a combination of BBM/PA4 with ABT199 will exhibit a synergistic effect in DHL. We also demonstrated PA4 as a more potent inhibitor of cancer cell growth than BBM. According to our results, treatment with the PA4 effectively inhibited both c-Myc and BCL2, which impaired both STAT3 and NFAT signaling pathways. We contextualize these results by discussing the relationship between CAMKII and downstream targets in DHL.

2 | METHODS

2.1 | Patient specimens

Paraffin sections of DLBCL patients (n = 28) and DHL patients (n = 10) were obtained from the Department of Pathology Qingdao University Medical College Affiliated Yantai Yuhuangding Hospital. All the collections of samples were carried out with informed consent according to the Declaration of Helsinki. Ethical approval was provided by the Ethics Committee of Qingdao University Medical College Affiliated Yantai Yuhuangding Hospital.

2.2 | Cell lines and reagents

Four DHL cell lines (NU-DHL-1, SU-DHL-6, OCI-LY-19 and DOGKIT) and a Burkitt cell lymphoma cell line (Jiyoye) were employed. NU-DHL-1, SU-DHL-6 and OCI-LY-19 were maintained in IMDM (Corning) with 10% FBS (Omega Scientific), DOGKIT and Jiyoye were maintained in RPMI 1640 (Corning) with 10%FBS. All the cells were cultured at 37°C in a 95% air, 5% CO2 humidified incubator.

BBM, PA4, and ABT199 (Millpore Sigma) were dissolved in stock solutions with dimethyl sulfoxide (DMSO) for treatment at IC50 concentrations if not otherwise indicated. All antibodies and other reagents used are listed in Table S1.

2.3 | IHC analysis

Immunohistochemical (IHC) staining for patients’ samples was described in supplementary information. Tumors harvested from mice were fixed in 4% PBS-buffered formaldehyde solution, dehydrated, and embedded in paraffin. Paraffin-embedded samples were sectioned and processed for hematoxylin and eosin (H&E) staining and IHC staining. The staining was performed by the Pathology Core of City of Hope Medical Center.

2.4 | MTS ASSAYS

Cells cultured in 96-well plates and exposed to different concentrations of BBM/PA4/ABT199 for 24 h. Cell viability was determined by CellTiter 96 Aqueous Cell Proliferation Kit (Promega). IC50 was defined as the drug concentration that induced a 50% viability decrease.

2.5 | Gene knockout using the CRISPR/Cas9 system

Single guide RNA (sgRNA) sequences targeting exon seven of human CAMK2D and exon one of CAMK2G were designed using the CRISPR on-line design tool (www.genome-engineering.org/crispr; Table S2). The designed sequences were cloned into pSpCas9(BB)-2A-GFP (PX458, Addgene) and validated by Sanger sequencing (Figure S3A). The sgRNA-containing pX458 was electroporated into SU-DHL-6 cells with the Cell Line Nucleofector Kit V (Lonza) following manufacturer instructions. Forty-eight hours later, single green fluorescent protein-positive (GFP+) cells were sorted by FACS into 96-well plates and expanded to individual clones. Single clones were screened by qPCR with two pairs of primers (Table S2) covering the cutting site of CAMK2D and CAMK2G. Compared with wide type
and lower positive cell rate (Figure 1A,B). In different subgroups of the non-germinal center B-DLBCL, both CAMKII and CAMKIIδ exhibited a cytoplasmic expression pattern. The expression pattern of CAMKII was frequently and DHL cases (8/10, 80%; Figure 1A). All CAMKII highly expressed (IHC score was similar to CAMKIIγ was similar to CAMKIIγ with a weaker staining intensity was confirmed. Western Blot analysis was performed to confirm knockout. 

2.6 | Xenograft model

Murine experiments were in accordance with a protocol approved by the Animal Care and Use Committee in City of Hope (Duarte, CA). 3 × 10^6 SU-DHL-6 cells suspended in RPMI 1640 were injected subcutaneously in the right flank of female NSG mice. After the xenografted tumors reached ~30 mm^3, mice were randomized to 2 groups: PBS control, n = 8; treated with 5 mg/kg PA4, n = 10. Mice were treated daily via oral gavage for 12 days. Tumors and body weight were measured three times a week with Vernier calipers, and the tumor volume was calculated as length × width^2/2. Mice were euthanized, and tumor tissues were collected after the 12th day of treatment.

2.7 | Statistical analysis

Difference between two groups was calculated by Mann-Whitney U test or Student’s t-test (two-sided). For intercomparison of more than 2 groups, a one-way ANOVA followed by a post-hoc test was applied. To assess the association between c-Myc and CAMKIIγ, Pearson correlation analysis was used. p values < 0.05 were considered statistically significant. In the figures, changes are noted using *p < 0.05 and **p < 0.01. Statistical analysis was conducted using SPSS or GraphPad Prism.

3 | RESULTS

3.1 | CAMKIIδ, CAMKIIγ, p-c-Myc (S62), c-Myc and BCL2 expressions were frequently observed in DLBCL and DHL patients

First the expression levels of five proteins—CAMKIIδ, CAMKIIγ, p-c-Myc (S62), c-Myc and BCL2 were assessed across clinical samples of DLBCL and DHL by immunohistochemistry (IHC). Among the 38 cases, IHC clearly detected expression of all proteins with variable frequency and intensity (Table 1). CAMKIIδ was frequently and highly expressed (IHC score ≥ 100) in both DLBCL cases (12/28, 43%) and DHL cases (8/10, 80%; Figure 1A). All CAMKIIδ positive cases exhibited a cytoplasmic expression pattern. The expression pattern of CAMKIIγ was similar to CAMKIIδ with a weaker staining intensity and lower positive cell rate (Figure 1A,B). In different subgroups of DLBCL, both CAMKIIδ and CAMKIIγ were significantly higher in the germinal center B-cell (GCB) and the DHL subgroups compared to the non-GCB group. To investigate the association between CAMKII

| No. | Cell origin | CAMKIIδ | CAMKIIγ | p-c-myc (s62) | c-Myc | Bcl-2 |
|-----|-------------|---------|---------|---------------|-------|-------|
| 1   | Non-GCB     | 0       | 0       | 34            | 5%    | +     |
| 2   | Non-GCB     | 106.2   | 41.6    | 188.6         | 30%   | -     |
| 3   | Non-GCB     | 78.8    | 0       | 58.4          | 30%   | +     |
| 4   | Non-GCB     | 32.8    | 0       | 50.8          | 10%   | +     |
| 5   | Non-GCB     | 10.8    | 5.6     | 74.0          | -     | -     |
| 6   | Non-GCB     | 53.8    | 0       | 22.8          | 10%   | +     |
| 7   | Non-GCB     | 1.6     | 0.6     | 5.6           | 20%   | +     |
| 8   | Non-GCB     | 0       | 0       | 0             | -     | +     |
| 9   | Non-GCB     | 78.2    | 0       | 0             | 10%   | 60%   |
| 10  | Non-GCB     | 183.6   | 87.4    | 0             | 30%   | -     |
| 11  | Non-GCB     | 127.0   | 1.4     | 84.6          | 40%   | -     |
| 12  | GCB         | 114.0   | 21.4    | 9.2           | 10%   | +     |
| 13  | Non-GCB     | 34.0    | 21.4    | 9.2           | 30%   | 70%   |
| 14  | GCB         | 154.0   | 0       | 106.8         | 50%   | 50%   |
| 15  | GCB         | 86.0    | 10.4    | 12.6          | 20%   | 60%   |
| 16  | Non-GCB     | 183.6   | 87.4    | 0             | 30%   | -     |
| 17  | Non-GCB     | 127.0   | 1.4     | 84.6          | 40%   | -     |
| 18  | Non-GCB     | 34.0    | 21.4    | 9.2           | 30%   | 70%   |
| 19  | GCB         | 124.8   | 107.4   | 158.2         | 60%   | -     |
| 20  | GCB         | 112.2   | 84.8    | 52.6          | 40%   | 50%   |
| 21  | DHL         | 181.4   | 82.6    | 177.8         | -     | -     |
| 22  | GCB         | 55.4    | 53.8    | 187.6         | -     | -     |
| 23  | Non-GCB     | 11.2    | 0       | 63.4          | 50%   | -     |
| 24  | GCB         | 67.8    | 0       | 112           | 70%   | 50%   |
| 25  | Non-GCB     | 118.0   | 0       | 96.6          | 40%   | +     |
| 26  | GCB         | 105.4   | 0       | 69.8          | 60%   | 30%   |
| 27  | Non-GCB     | 0       | 0       | 0             | 40%   | 70%   |
| 28  | GCB         | 31.0    | 17.2    | 64.4          | 50%   | 80%   |
| 29  | DHL         | 113.4   | 0       | 85.2          | 40%   | -     |
| 30  | GCB         | 170.8   | 42.6    | 61            | 40%   | -     |
| 31  | DHL         | 218.0   | 125.4   | 147.2         | -     | +     |
| 32  | DHL         | 240.6   | 164.4   | 186           | -     | -     |
| 33  | DHL         | 162.0   | 134.8   | 198.4         | 90%   | +     |
| 34  | DHL         | 190.4   | 117     | 185.6         | 90%   | +     |
| 35  | DHL         | 15.0    | 157.8   | 0             | -     | -     |
| 36  | DHL         | 158.8   | 196.2   | 149           | +     | +     |
| 37  | DHL         | 95.6    | 41      | 137.2         | 90%   | -     |
| 38  | DHL         | 182.4   | 104     | 125.8         | -     | +     |

Note: GCB: n = 10; Non-GCB: n = 18; DHL: n = 10.
FIGURE 1  Positive correlations of expressions detected by Immunohistochemical (IHC) staining among Ca²⁺/calmodulin-dependent protein kinase II δ (CAMKIIδ), Ca²⁺/calmodulin-dependent protein kinase II γ (CAMKIIγ), c-Myc and pS62-c-Myc in diffuse large B cell lymphoma (DLBCL) and double-hit lymphoma (DHL) patients. (A), Representative images of IHC staining of CAMKIIδ, CAMKIIγ, and pS62-c-Myc in DLBCL and DHL tissues. (B), IHC scores in subgroups of clinical cases subgrouped by the cell-of-origin (COO). (C), IHC scores of CAMKIIδ and CAMKIIγ subgrouped by c-Myc or BCL2 expression. (D), Correlations between CAMKIIδ (left) or CAMKIIγ (right) and pS62-c-Myc expression in human DLBCL and DHL samples. Data are shown as mean ± SEM and compared by unpaired Student’s t-test. Correlations are shown using Pearson’s r and significance determined using a Spearman correlation. *p < 0.05; **p < 0.01.
and c-Myc, patients were separated into Myc-positive (Myc+) and Myc-negative (Myc-) groups (cutoff 40%). Myc+ group exhibited a higher CAMKKI6 staining score than Myc- group (Figure 1C left). Pearson correlation analysis showed a positive correlation between expression of both CAMKKI6/γ and p-c-Myc (S62), c-Myc (Figure 1D). We also compared CAMKKI6/γ in BCL2-negative (BCL2-) and BCL2-positive (BCL2+) groups (cutoff 50%), but no significant difference was found (Figure 1C right).

### 3.2 BBM or PA4 effectively inhibited DHL cell growth and induced cell apoptosis

The expression of c-Myc and CAMKKI6/γ in four DHL cell lines was examined compared to Burritt’s lymphoma cell line Jiyoye (Figure 2A). All four DHL cell lines expressed higher levels of CAMKKI6/γ, c-Myc, and BCL2. We first determined the effects of BBM and PA4 on cell growth and apoptosis. Both BBM and PA4 inhibited cell growth in a dose-dependent manner (Figure 2B,C), while PA4 possessed a much lower IC50 concentration (Figure 2B), suggesting a more potent inhibitor of proliferation.

Cell apoptosis was measured in DHL cell lines after 24-h treatment. Approximately 72.67%–91.57% of cells treated with PA4 were positive for Annexin V; whereas the positive rates were limited to 30%–50% treated with BBM (Figure 2D). These results suggest that PA4 is more effective than BBM at inducing apoptosis.

As a selective inhibitor of BCL2, ABT199 is a promising drug for DHL. ABT199 inhibited cell growth of DOGKIT and SU-DHL-6 (Figure 3A). Synergistic effects of two different combinations: (1) BBM + ABT199 and (2) PA4 + ABT199 were explored. CI values were calculated to determine the synergistic effects based on previous literature. We observed a low synergistic effect for BBM + ABT199 (CI50 = 0.7978 in SU-DHL-6). In contrast, a high synergistic effect was observed for PA4 + ABT199 (CI50 = 0.3672 in SU-DHL-6; CI50 = 0.5120 in DOGKIT; Figure 3B). Neither of the combinations displayed a clear synergistic effect on cell apoptosis (Figures 3C,D). Compared to ABT199 treatment alone, a slightly higher number of early apoptotic cells in DOGKIT BBM + ABT199 combination and higher percentage of apoptotic cells in SU-DHL-6 BBM + ABT199 and PA4 + ABT199 combinations were observed.

### 3.3 PA4 bound to both CAMKKIγ and CAMKKIδ and displayed higher affinity compared to BBM

The structures of BBM and PA4 are shown in Figure 4A. We previously identified that BBM can bind and inhibit CAMKKIγ by targeting its ATP binding pocket. Here, docking between PA4 and CAMKKIγ was performed with the Glide docking method. PA4 also displayed the capacity to target the ATP binding pocket of both CAMKKIγ and CAMKKIδ (Figures 4B,C).

To probe binding of the compounds to CAMKKIδ/γ via in vitro experiments, DARTS analysis was performed (Figure S2). Cell lysate was incubated with increasing concentrations of either BBM or PA4; then protease solution was added to digest the protein. The physical binding of the compounds to both CAMKKIγ and CAMKKIδ can protect the proteins from proteolysis in the assay, resulting in higher amounts of undigested proteins detected by western blot (Figure 4D). PA4 exhibited a much lower effective concentration in protecting CAMKKIδ/γ from proteolysis.

### 3.4 BBM or PA4 inhibits phosphorylation of CAMKKIγ/δ, leading to the instability of c-Myc protein and downregulation of other oncogenic pathways

Furthermore, downstream molecular pathway alterations after BBM or PA4 treatment were assessed. Western blot showed CAMKKIγ and CAMKKIδ as well as total c-Myc and p-c-Myc (S62) were significantly downregulated by either BBM or PA4 in a dose dependent manner (Figure 5A). Our previous studies demonstrated that CAMKKIγ stabilized c-Myc by directly phosphorylating it at S62. The data from DHL cells suggests that the c-Myc is affected by the status of both CAMKKIγ and CAMKKIδ similarly.

Compensatory upregulation of mRNA was observed in CAMKK2G and CAMKK2D of DOGKIT as well as CAMKK2G of SU-DHL-6. Similarly, MYC transcription was compensatory increased after long-term exposure to PA4 in DOGKIT (Figure 5B). Other important genes related to DLBCL growth, such as STAT3 and NFAT pathway are also determined. Here, treatment of DHL cell lines with either BBM or PA4 decreased STAT3 activation and reduced both NFATc1 and NFATc2 levels (Figure 5A). Both STAT3 and NFAT mRNA significantly decreased after treatment (Figure 5B), suggesting the reduction of STAT3 and NFAT was due to impaired gene transcription. Transcription of NFAT downstream target, such as interferon regulatory factor 4 (IRF4) also decreased. In contrast, IL10, which is up regulated by NFAT, did not change after treatment (Figure 5B).

We also measured BCL2 levels in DHL cells. When DOGKIT cells were treated with either compound, protein levels of BCL2 were reduced. A similar effect was observed in SU-DHL-6 cells when treated with high concentrations (Figure 5A). Consistently, the transcription of BCL2 were markedly decreased in both DOGKIT and SU-DHL-6 cells after either BBM or PA4 treatment (Figure 5B).

### 3.5 CAMKKI deletion similarly inhibits the growth of DHL cells

To better understand the impact of CAMKKI in DHL, we used the CRISPR/Cas9 system to generate CAMKKI knockout (KO) cell lines in SU-DHL-6. After single cell clone selection, we generated CAMKKIδ KO, CAMKKIγ KO, and CAMKKIδ/γ double knockdown (DKD) cell lines (Figure 6A). We failed to obtain CAMKKIδ/γ double knockout clones, suggesting that double knockout of CAMKKIδ/γ may be detrimental to cells.
Characteristics and inhibitory effect of BBM, PA4 and ABT199 on four double-hit lymphoma (DHL) cell lines. (A), Western blot analysis of Ca²⁺/calmodulin-dependent protein kinase II δ (CAMKIIδ), Ca²⁺/calmodulin-dependent protein kinase II γ (CAMKIIγ), phosphorylated c-Myc (ser62), c-Myc, and BCL2 in four DHL cell lines (DOGKIT, SU-DHL-6, NU-DHL1, and OCI-LY-19). Jiyoye is a Burkitt lymphoma cell line used here as a comparison. (B), IC₅₀ concentrations at 24 h of BBM and PA4 for four DHL cell lines and Jiyoye determined by MTS assay. (C), Cell viability determined by MTS assay in DHL cell lines. DHL cell lines were treated with either BBM or PA4 at increasing concentrations. Cell viability was determined by MTS assay at 24 h and normalized to vehicle control. (D), Apoptosis induced by either BBM (20 µM) or PA4 (2 µM) when the treatments were applied to cell lines for 24 h. Cells were stained with Annexin V and DAPI and then evaluated on BD Fortessa cytometer. The collected data were analyzed by FlowJo software. Data are shown as mean ± SEM and significance are determined by unpaired Student’s t-test. *p < 0.05 compared to vehicle; **p < 0.01 compared to vehicle.
FIGURE 3  Synergistic effect of BBM/PA4 with ABT199 on DOGKIT and SU-DHL-6. (A), IC_{50} concentrations of ABT199 for double-hit lymphoma (DHL) cell lines determined by MTS assay. (B), Synergistic effects of treatments in DOGKIT and SU-DHL-6. DOGKIT and SU-DHL-6 were either treated with an individual agent (BBM, PA4, or ABT199) or with two of these agents (ABT199 + X) at increasing concentrations. Cell viability was determined by MTS assay at 24 h and normalized to vehicle control. (C), Apoptotic cells 8 h after combined treatment analyzed by Flowjo. D, Early and late apoptosis induced by ABT199 (50 nM), BBM (10 µM), PA4 (1 µM), BBM (10 µM) + ABT199 (50 nM), or PA4 (1 µM) + ABT199 (50 nM). Data are shown as mean ± SEM and significance are determined by unpaired Student’s t-test. *p < 0.05 compared to vehicle; **p < 0.01 compared to vehicle; #p < 0.05 compared to ABT199; ##p < 0.01 compared to ABT199
Figure 4  PA4 binds to Ca\(^{2+}\)/calmodulin-dependent protein kinase II γ (CAMKIIγ) and Ca\(^{2+}\)/calmodulin-dependent protein kinase II δ (CAMKIIδ) and shows higher affinity compared to BBM. (A), Molecular weights and constructs of BBM and PA4. (B), Interactions of PA4 at the ATP-binding pocket of CAMKIIγ. The hydrogen bonds are displayed as green dots, while the hydrophobic interaction pairs are shown as gray arrows. n-Interaction pairs are depicted as yellow arrows. (C), Two-dimensional interaction diagram of PA4 bound to the ATP-binding pocket of CAMKIIδ. (D), DARTS analysis was performed to identify potential protein targets for BBM and PA4. The cell lysate of SU-DHL-6 was incubated with increasing concentrations of either BBM or PA4 at room temperature for 30 min. Then a protease solution was added into the mixtures to digest the protein. Proteins in the digested products were detected with western blot analysis.

Compared to the wild type (WT) parental cells, KO cell lines displayed lower proliferation capacity and higher apoptotic rate (Figure 6B and Figure S4A). KO cell lines were more resistant to either BBM or PA4 with higher IC\(_{50}\) (Figure S4B). KO cell lines exhibited mildly reduced MYC mRNA and significantly reduced BCL2 mRNA. KO cell lines also significantly decreased mRNA levels of STAT3, NFATc1, and NFATc2 (Figure 6C). Downstream target of NFAT pathway, IL10 and IRF4 mRNA were also downregulated (Figure 6C).

The decreased mRNA transcription in the KO cell lines (Figure 6C) correlated with reduced protein expression of c-Myc, STAT3, NFATc1, NFATc2, and BCL2 (Figure 6A). Both c-Myc and p-c-Myc (S62) were reduced in KO cell lines with double knockdown had a more pronounced reduction than single deletion. STAT3 and NFAT protein levels were reduced in all KO cell lines. BCL2 protein level was significantly decreased in CAMKIIγ KO and DKD cells. The impact of CAMKII deletion via CRISPR/Cas9 was consistent with pharmacological inhibition using either BBM or PA4.

Furthermore, rescue experiments were performed. We transiently transfected SU-DHL-6 DKD cells with either CAMKIIδ, CAMKIIγ, or c-Myc plasmids. Exogenous expression of either CAMKIIδ, CAMKIIγ, or c-Myc partially rescued protein levels of BCL2, STAT3 and NFAT. Moreover, exogenous expression of either CAMKIIδ or CAMKIIγ upregulated c-Myc in SU-DHL-6 DKD cells (Figure 6D). These results suggest that the CAMKII-c-Myc axis is critical in DHL cell lines.
FIGURE 5  SU-DHL-6 and DOGKIT treated with BBM and PA4. (A), Western blot analysis of CAMKII and potential targets in SU-DHL-6 and DOGKIT treated by BBM or PA4 for 24 h at increasing concentrations. (B), mRNA levels of SU-DHL-6 and DOGKIT treated by BBM (30 µM for SU-DHL-6 and 15 µM for DOGKIT) or PA4 (3 µM for SU-DHL-6 and 1.5 µM for DOGKIT). Data are shown as mean ± SEM and significance are determined by unpaired Student's t-test. *p < 0.05; **p < 0.01
FIGURE 6 Deleting CAMKII affected biological features by decreasing the stability of c-Myc and impairing transcriptions of downstream targets. (A), Western blot analysis of CAMKII and potential targets in independent single cell clones of wide type (WT), Ca\(^{2+}\)/calmodulin-dependent protein kinase II δ (CAMKIIδ) KO, Ca\(^{2+}\)/calmodulin-dependent protein kinase II γ (CAMKIIγ) KO, and CAMKIIδ/γ DKO in SU-DHL-6. (B), Growth curve of WT and CAMKII deficient cells determined by MTS assay (upper panel). Percentages of apoptotic cells determined by flow cytometry. Cells were stained with Annexin V and DAPI and then evaluated on BD Fortessa cytometer. The collected data were analyzed by FlowJo software. (C), Exogeneous CAMKIIδ or CAMKIIγ or c-Myc was expressed by the transiently transfected plasmids in CAMKIIδ/γ DKD cell line and harvested cells 24 h after transfection. Western blot analysis. (D), mRNA levels of CAMKII deficient cells. Data are shown as mean ± SEM and significance are determined by unpaired Student’s t-test. *p < 0.05 compared to WT; **p < 0.01 compared to WT
FIGURE 7  PA4 exhibited promising therapeutic effect in vivo. (A). Tumor growth curve in NSG mice treated with either PA4 or PBS for 12 days (left panel) and tumor size at endpoint of the 12th day (right panel). (B), Tumors size on day 12. (C). mRNA level of IL10, IRF4, MKI67, MYC and BCL2 in tumor tissues from PA4 and PBS groups. (D), Western blot analysis of CAMKII and potential targets in tumor tissues from PA4 and PBS groups. (E), Representative images of HE, Immunohistochemical (IHC), and TUNEL staining with sections of tumors from PA4 and PBS groups.
3.6 | PA4 exhibited a potent therapeutic effect on DHL in animal tumor models

To evaluate the anti-tumor effects of PA4 in vivo, we adopted a xenograft model using NSG mice inoculated with SU-DHL-6 cells. Single treatment of PA4 at a dosage of 5 mg/kg/d was sufficiently to control tumor growth in these animals (Figure 7A). When we euthanized the mice on day 12, tumor volume in PA4 group was markedly smaller than PBS group (Figure 7B).

Compared to PBS group, we observed reductions of NFAT mRNA and proteins (Figure 7C,D), with notable reductions of downstream IL10 and IRF4 mRNA. IHC staining showed weaker stained Ki67 in PA4 treatment group (Figure 7E). The STAT3 pathway, c-Myc and BCL2 were all strongly reduced after PA4 treatment (Figures 7D,E). Higher cell apoptosis was detected in the PA4 group as shown by TUNEL staining (Figure 7E).

4 | DISCUSSION

In DHL, characteristic gene rearrangements lead to overexpression of MYC/BCL2 that promote tumor cell growth and survival.14,15 Patients with this unique subtype of lymphoma have poor outcomes.2,16 In this study, we tested the natural product BBM and its analog PA46,7,17,18 as inhibitors of CAMKII in DHL. Our results indicate that CAMKIIδ is the dominant isotype expressed in DHL cell lines and is associated with high levels of c-Myc. Treatment with either BBM or PA4 can significantly inhibits DHL development in vitro and in vivo.

In our previous study on T cell lymphoma (6), we demonstrated that CAMKIIδ stabilizes c-Myc by directly phosphorylating it at Serine 62 (S62); this leads to cellular proliferation and lymphoma-genesis.19–21 Our results in DHL here showed the same mechanism. Pharmacological inhibition of CAMKII with either BBM or PA4 impedes phosphorylation at S62 and results in degradation of c-Myc protein regardless of the high mRNA levels. This is critical because DHL has higher MYC transcription due to the MYC rearrangement. We observed similar c-Myc degradation when we genetically delete both CAMKIIδ/γ in SU-DHL-6.

Another potential target of CAMKII is the STAT3 pathway.22,23,24 Constitutive STAT3 activation is frequently observed in hematological malignancies,25–29 and has been associated with poor outcomes.30–33 STAT3 can be directly phosphorylated at S727 by CAMKII24,34, which is critical for STAT3 transcriptional activity. Furthermore, c-Myc is reported to be regulated by STAT3 pathway.35 Either BBM, PA4, or CAMKII deletion impeded STAT3 activation and may further contribute to c-Myc protein degradation.

Another important pathway in lymphomagenesis is NFAT pathway. NFAT pathway is chronically activated independent of BCR signaling and controls key biological processes in B cell lymphoma.12,13,36,37 The NFAT pathway was shown to be negatively regulated by CAMKII in a model of pathological cardiac myocyte hypertrophy.38 Our findings in DHL indicated that CAMKII inhibition lowered NFAT transcription and impaired NFAT activity. Interruption of the NFAT pathway in DHL cell lines may be indirectly induced by a reduction in c-Myc as either exogenous CAMKIIδ or c-Myc could rescue the NFAT transcription and activity.

We also observed that in DHL, the CAMKII-Myc axis unexpectedly regulated the downstream protein BCL2. BCL2 is the hallmark anti-apoptotic protein overexpressed in DHL and a promising target for DHL therapy. Targeting BCL2 with ABT199 effectively inhibits cell growth in DHL.34,39 In this study, the combination of ABT199 with PA4 exhibited a moderate synergistic effect in vitro, which may result from concurrent inhibition of BCL2 and c-Myc. In a report by Wei et al., BCL2 was shown to be regulated by CAMKII.40 Here, we also observed that BCL2 transcription is decreased when CAMKII is inhibited. Accordingly, we observed lower levels of BCL2 protein in NSG models treated with PA4.

In summary, we have demonstrated a critical role of CAMKII in accelerating proliferation and inhibiting apoptosis in DHL. Although the potential off-target effects of BBM and PA4 need further verification and improvement for a future drug development, this study provides a proof-of-concept that targeting CAMKII by BBM and its derivative PA4 may lead to a promising DHL treatment using a single agent.

ACKNOWLEDGEMENTS

We particularly thank Drs. Larry Kwak, Christoph Pittius and Mingyue Zhou at City of Hope for their insightful input and Dr. Ian Talisman for reviewing and editing the manuscript. This work is supported partially by COH IDDv program and NCI R01CA139158 to W.H. and TSLC pilot grant award to W.C. and W.H. The work performed in the City of Hope Drug Discovery and Structural Biology Core as well as Chemistry Synthetic core is supported by the National Cancer Institute of the National Institutes of Health under award number P30CA033572.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS

Wendong Huang, Xiaoxia Chu and Wing C. Chan conceptualized, designed the experiments, and revised the manuscript. Xiaojian Liu, Senlin Xu, Jiawei Zhang and Mingjie Fan designed the experiments, analyzed data, wrote the manuscript. Hongzhi Li, Jun Xie and Bingfeng Zhang performed in the compound synthesis. Guohua Yu, Yinghui Liu, Yuanfeng Zhang, Joo Song, and J.W. performed IHC staining, accessed IHC scores and did animal studies. David Horne advised and revised the manuscript.

ETHICS STATEMENT

All the collections of samples were carried out with informed consent according to the Declaration of Helsinki. Ethical approval was provided by the Ethics Committee of Qingdao University Medical College Affiliated Yantai Yuhuangding Hospital (Yantai, China). Murine experiments were in accordance with a protocol approved by the Animal Care and Use Committee in City of Hope (Duarte, CA).
DATA AVAILABILITY STATEMENT
All data, models, and code generated or used during the study appear in the submitted article.

ORCID
Senlin Xu https://orcid.org/0000-0001-6625-5370
Yuanfeng Zhang https://orcid.org/0000-0001-8405-0053
Xiaoxia Chu https://orcid.org/0000-0002-0963-1576
Wendong Huang https://orcid.org/0000-0003-3735-9466

TRANSPARENT PEER REVIEW
The peer review history for this article is available at https://publons.com/publon.10.1002/hon.3010.

REFERENCES
1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390. https://doi.org/10.1182/blood-2016-01-643559
2. Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354-2361.
3. Cinar M, Rosenfelt F, Rokhsar S, et al. Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas. Leuk Res. 2015;39(7):730-738. https://doi.org/10.1016/j.leukres.2015.04.003
4. Uchida A, Isobe Y, Asano J, et al. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteineexpression" lymphoma with MYC and BCL2 rearrangements. Haematologica. 2019;104(7):1417-1421. https://doi.org/10.3324/haematol.2018.204958
5. Zhang X, Bi C, Lu T, et al. Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas. Leukemia. 2019;33(3):138-150. https://doi.org/10.1038/s41375-019-0503-z
6. Gu Y, Zhang J, Ma X, et al. Stabilization of the c-myc protein by CaMKIIamma promotes T cell lymphoma. Cancer Cell. 2017;32(1):115-128, e7. https://doi.org/10.1016/j.ccell.2017.06.001
7. Gu Y, Chen T, Meng Z, et al. CaMKII gamma, a critical regulator of cancer stem/progenitor cells, is a target of the natural product berbamine. Blood. 2012;120(24):4829-4839. https://doi.org/10.1182/blood-2012-06-434894
8. Seuvers AJ, Levenson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202-208. https://doi.org/10.1038/nm.3048
9. Johnson-Farley N, Veliz J, Bhagavathi S, Bertino JR. ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells. Leukemia. 2015;29(7):2146-2152. https://doi.org/10.1038/leukemia.2014.981
10. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621-681. https://doi.org/10.1124/pr.58.3.10
11. Pulverer BJ, Fisher C, Vosden K, Littlewood T, Evan G, Woodgett JR. Site-specific modification of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene. 1994;9(1):59-70.
12. Bucher P, Erdmann T, Grondona P, et al. Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma. Blood. 2020;135(2):121-132. https://doi.org/10.1182/blood.2019001866
13. Li L, Zhang J, Chen J, et al. B-cell receptor-mediated NFAT1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma. Blood. 2018;132(17):1805-1817. https://doi.org/10.1182/blood-2018-03-841015
14. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood. 2011;117(8):2319-2331. https://doi.org/10.1182/blood-2010-09-297879
15. Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166(6):891-901. https://doi.org/10.1111/bjh.12982
16. Tomita N, Tokunaka M, Nakamura N, et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica. 2009;94(7):935-943. https://doi.org/10.3324/haematol.2008.005355
17. Dong QH, Zheng S, Xu RZ, Lu Q, He L. [Study on effect of berbamine on multidrug resistance leukemia K562/Adr cells]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2004;24(9):820-822.
18. Xie J, Ma T, Gu Y, et al. Berbamine derivatives: a novel class of compounds for anti-leukemia activity. Eur J Med Chem. 2009;44(8):3293-3298. https://doi.org/10.1016/j.ejmech.2009.02.018
19. Farrell AS, Sears RC. MYC degradation. Cell Cycle. 2014;13(5):2146-2149. https://doi.org/10.1002/cctc.201301865
20. Malmepati S, Tibbitts D, Cunningham M, et al. Aberrant stabilization of c-Myc protein in some lymphoblastic leukemias. Leukemia. 2006;20(9):1572-1581. https://doi.org/10.1038/sj.leu.2404317
21. Zhang X, Farrell AS, Daniel CJ, et al. Mechanistic insight into MYC stabilization in breast cancer involving aberrant Axin1 expression. Proc Natl Acad Sci USA. 2012;109(8):2799-2795. https://doi.org/10.1073/pnas.1107641108
22. Zhang L, Tong J, He X, et al. Novel synthetic 4-chlorobenzoyl berbamine inhibits c-Myc expression and induces apoptosis of diffuse large B cell lymphoma cells. Ann Hematol. 2018;97(12):2353-2362. https://doi.org/10.1007/s00277-018-3439-x
23. Unudurthi SD, Nassal D, Greer-Short A, et al. beta1IV-Spectrin regulates STAT3 targeting to tune cardiac response to pressure overload. J Clin Invest. 2018;128(12):5561-5572. https://doi.org/10.1172/jci99245
24. Si J, Collins SJ. Activated Ca2+/calmodulin-dependent protein kinase II gamma is a critical regulator of myeloid leukemia cell proliferation. Cancer Res. 2008;68(10):3733-3742. https://doi.org/10.1158/0008-5472.can-07-2509
25. Ding BB, Yu JJ, Yu RY, et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood. 2008;111(3):1515-1523. https://doi.org/10.1182/blood-2007-04-087734
26. Huang X, Meng B, Iqbal J, et al. Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(36):4520-4528. https://doi.org/10.1200/jco.2012.45.6004
27. Nelson EA, Walker SR, Kepich A, et al. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood. 2008;112(13):5095-5102. https://doi.org/10.1182/blood-2007-12-129718
28. Kube D, Holtick U, Vockerodt M, et al. STAT3 is constitutively activated in Hodgkin cell lines. Blood. 2001;98(3):762-770. https://doi.org/10.1182/blood.v98.3.762
29. Chiarle R, Simmons WJ, Cai H, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med. 2005;11(6):623-629. https://doi.org/10.1038/nm1249
30. Fukuda A, Wang SC, Morris JP, et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell. 2011;19(4):441-455. https://doi.org/10.1016/j.ccr.2011.03.002

31. Spitzner M, Ebner R, Wolff HA, Ghadimi BM, Wienands J, Grade M. STAT3: a novel molecular mediator of resistance to chemoradiotherapy. Cancers (Basel). 2014;6(4):1986-2011. https://doi.org/10.3390/cancers6041986

32. Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234-248. https://doi.org/10.1038/nrclinonc.2018.8

33. Song TL, Nairismagi ML, Laurensia Y, et al. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. Blood. 2018;132(11):1146-1158. https://doi.org/10.1182/blood-2018-01-829424

34. Shen Y, Schlessinger K, Zhu X, et al. Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation. Mol Cell Biol. 2004;24(1):407-419. https://doi.org/10.1128/mcb.24.1.407-419.2004

35. Huang L, Liu D, Wang N, et al. Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. Cell Res. 2018;28(2):172-186. https://doi.org/10.1038/cr.2017.146

36. Teixeira LK, Carrossini N, Secca C, et al. NFAT1 transcription factor regulates cell cycle progression and cyclin E expression in B lymphocytes. Cell cycle. 2016;15(17):2346-2359. https://doi.org/10.1080/15384101.2016.1203485

37. Kondo E, Harashima A, Takabatake T, et al. NF-ATc2 induces apoptosis in Burkitt's lymphoma cells through signaling via the B cell antigen receptor. Eur J Immunol. 2003;33(1):1-11. https://doi.org/10.1002/immu.200390000

38. MacDonnell SM, Weisser-Thomas J, Kubo H, et al. CaMKII negatively regulates calcineurin-NFAT signaling in cardiac myocytes. Circulation Res. 2009;105(4):316-325. https://doi.org/10.1161/circresaha.109.194035

39. Han L, Zhang Q, Dail M, et al. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica. 2019;105(3):697-707. https://doi.org/10.3324/haematol.2018.205534

40. Wei G, Chen YB, Chen DF, et al. beta-Asarone inhibits neuronal apoptosis via the CaMKII/CREB/Bcl-2 signaling pathway in an in vitro model and AbetaPP/PS1 mice. J Alzheimers Dis. 2013;33(3):863-880. https://doi.org/10.3233/jad-2012-120865

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Liu X, Xu S, Zhang J, et al. Targeting MYC and BCL2 by a natural compound for “double-hit” lymphoma. Hematol Oncol. 2022;40(3):356-369. https://doi.org/10.1002/hon.3010